Posts in category Insights


Intel Corporation Draws a Price Target Lift; Here’s Why

MKM’s Ruben Roy now spotlights 9% return potential for INTC shares, enticed by valuation ahead of what should be a “strong” 2018.

What to Expect Ahead of Teva Pharmaceutical Industries Ltd (ADR) Q4:17 Earnings: Oppenheimer

Oppenheimer’s Derek Archila says Teva shares are “not cheap” considering the risk factor of the new cost-cutting plan and headwinds circling.

All Eyes on Netflix, Inc. 4Q Earnings Tonight

Two analysts are weighing in cheering strong subscriber growth ahead of Netflix’s fourth quarter print this evening.

Amazon.com, Inc.: A Close Race for Second Headquarters “Lotto” Prize

GBH Insights’ analyst Daniel Ives weighs in on Amazon’s next big move: the expansion of its “consumer empire” with a second headquarters.

Synergy Pharmaceuticals: Analyst Questions Whether Label Expansion for Trulance Will Prove to Be a “Meaningful” Driver

Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first …

RBC Capital Dials Up EPS Estimates on General Motors Company Following Detroit Auto Show

RBC Capital’s Joseph Spak pinpoints 21% upside potential for General Motors stock, betting GM International is nearing breakeven by 2019.

Apple Inc.: Should You Be Worried About iPhone X Cuts? Analyst Jun Zhang Shares Two Cents

Rosenblatt’s Jun Zhang says he looks for iPhone X cuts in the first fiscal quarter to circle 3 million- not the massive 10 million bears are expecting.

Tesla Inc May Be at Risk for More Bottlenecks in Production, Joseph Spak Warns

RBC’s Joseph Spak cuts his estimates on Tesla following 4Q17 production/delivery results and on the heels of last week’s Detroit Auto Show.

Analyst Sees Over 160% Upside for IntelliPharmaCeutics Intl Inc (USA) Stock

It can be tricky putting a price tag on a biotech company, especially one that …

Show More